---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026349"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:27:32.386574+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics reports FY2022 net loss of $112.7M; cash $339.2M, runway into 2025

## Summary
- Net loss of $30.0M in Q4 2022 ($1.01/share) and $112.7M for FY2022 ($3.80/share), vs $18.0M and $66.8M in prior year.
- Cash and equivalents $339.2M at Dec 31, 2022, down from $438.7M; expected to fund operations into 2025.
- R&D expenses rose to $81.6M in FY2022 from $44.9M, driven by clinical programs for BT5528, BT8009, and TICA platform.
- BT8009 granted FDA Fast Track Designation for urothelial cancer; Phase II expansion initiated with RP2Ds established.
- BT5528 continues in dose expansion; BT7480 in dose escalation; pipeline updates expected later in 2023.

## SEC filing metadata
- accession: 0001104659-23-026349
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/0001104659-23-026349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/tm237668d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026349
- JSON: https://secwatch.observer/filing/0001104659-23-026349.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026349.txt

## Key facts
- Earnings Releases
  BICYCLE THERAPEUTICS PLC reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202, EPS $(1.01) basic and diluted net loss per share.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Net income: Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202
  - EPS: $(1.01) basic and diluted net loss per share
  - Result: reported results
  source text: On February 28, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2022 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/0001104659-23-026349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.